OpRegen Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving OpRegen Growth

1. Large Unmet Need in Dry AMD and Geographic Atrophy

The strongest growth driver for OpRegen is the large patient population with limited treatment options.

• Age-related macular degeneration affects over 30 million people worldwide.
• Approximately 85-90% of AMD cases are the dry form.
• Around 1.6 million new AMD cases occur annually in the United States.

Geographic atrophy (advanced dry AMD) is a leading cause of irreversible vision loss in elderly populations. Because there are still few effective therapies capable of restoring vision, regenerative cell therapy approaches like OpRegen address a major unmet clinical need.

Market implication:

With aging populations globally, the addressable patient population is expected to expand significantly, creating a large commercial opportunity.

2. First-in-Class Regenerative Cell Therapy Approach

OpRegen is differentiated from currently approved therapies because it aims to replace damaged retinal pigment epithelial cells.

Mechanism of action:

• Transplantation of allogeneic RPE cells into the subretinal space
• Restoration of retinal support functions
• Potential regeneration of damaged retinal tissue

This regenerative approach could offer functional vision improvement, which current complement inhibitors primarily do not achieve.

Clinical evidence has shown:

• Mean visual acuity gains of ~6.2 letters overall
• Up to ~9 ETDRS letters in patients with extensive cell coverage
• Sustained anatomical improvements for up to 36 months after a single treatment.

Such long-term efficacy signals strong potential for commercial adoption if confirmed in later-stage trials.

3. Potential One-Time Treatment Advantage

A major competitive advantage for OpRegen is the possibility of one-time treatment.

• CEO commentary indicates treatment effects may last 24 months or longer after a single administration.
• This contrasts with current GA therapies that often require frequent injections.

Commercial advantages include:

• Improved patient compliance
• Lower lifetime treatment burden
• Potential cost advantages for healthcare systems.

If validated, this durability could drive strong physician and patient preference, accelerating adoption.

4. Strategic Partnership with Roche / Genentech

The collaboration with Roche significantly strengthens OpRegen's commercialization prospects.

Key terms of the partnership:

• Up to $670 million in development and commercialization milestone payments.
• $50 million upfront payment already received.
• Double-digit royalties on future global sales.

Benefits of the partnership include:

• Global development expertise
• Strong regulatory capabilities
• Large-scale commercial infrastructure in ophthalmology.

Roche's involvement substantially increases the probability of successful late-stage development and global commercialization.

5. Favorable Regulatory Designation

OpRegen has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.

RMAT designation provides several regulatory advantages:

• Accelerated clinical development pathways
• Increased interaction with regulators
• Potential for faster approval timelines.

This designation highlights the therapy's potential to address serious conditions with high unmet medical need.

6. Advancements in Manufacturing and Scalability

Commercial scalability is critical for cell therapies.

Lineage has reported progress in commercial-scale GMP manufacturing, allowing:

• Production of millions of potential cell therapy doses
• Consistent product quality
• Lower cost per treatment at scale.

These capabilities reduce one of the major barriers to commercialization in regenerative medicine.

OpRegen Recent Developments

• In June 2025, Lineage Cell Therapeutics announced 36-month results from a Phase I/IIa clinical study (NCT02286089) of RG6501 (OpRegen) for the treatment of geographic atrophy (GA), secondary to age-related macular degeneration (AMD).

"OpRegen Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of OpRegen for potential indication like Dry age-related macular degeneration and Dry macular degeneration in the 7MM. A detailed picture of OpRegen's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the OpRegen for potential indications. The OpRegen market report provides insights about OpRegen's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OpRegen performance, future market assessments inclusive of the OpRegen market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OpRegen sales forecasts, along with factors driving its market.

OpRegen Drug Summary

OpRegen (RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics in collaboration with Roche/Genentech, consisting of human retinal pigment epithelial (RPE) cells derived from embryonic stem cells via directed differentiation, administered as a single subretinal suspension injection to treat geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It aims to replace dysfunctional RPE cells in GA lesions, providing structural and functional support to surviving photoreceptors by promoting retinal health, with Phase 1/2a trial data from Cohort 4 (less advanced GA patients) showing rapid outer retinal structure improvements on OCT as early as day 1 post-injection in cases of extensive lesion coverage, sustained through 36 months including external limiting membrane and RPE drusen complex restoration, alongside mean vision gains of +9 letters. Currently in a Phase 2a study optimizing surgical delivery and assessing safety in up to 60 patients using a "thaw-and-inject" formulation, it remains unapproved with no FDA designation or known adverse events reported to date. The report provides OpRegen's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the OpRegen Market Report

The report provides insights into:

• A comprehensive product overview including the OpRegen MoA, description, dosage and administration, research and development activities in potential indication like Dry age-related macular degeneration and Dry macular degeneration.
• Elaborated details on OpRegen regulatory milestones and other development activities have been provided in OpRegen market report.
• The report also highlights OpRegen's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The OpRegen market report also covers the patents information, generic entry and impact on cost cut.
• The OpRegen market report contains current and forecasted OpRegen sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OpRegen market report also features the SWOT analysis with analyst views for OpRegen in potential indications.

Methodology:

The OpRegen market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OpRegen Analytical Perspective by DelveInsight

• In-depth OpRegen Market Assessment

This OpRegen sales market forecast report provides a detailed market assessment of OpRegen for potential indication like Dry age-related macular degeneration and Dry macular degeneration in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OpRegen sales data uptil 2034.

• OpRegen Clinical Assessment

The OpRegen market report provides the clinical trials information of OpRegen for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OpRegen Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OpRegen Market Potential & Revenue Forecast

• Projected market size for the OpRegen and its key indications
• Estimated OpRegen sales potential (OpRegen peak sales forecasts)
• OpRegen Pricing strategies and reimbursement landscape

OpRegen Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OpRegen Market positioning compared to existing treatments
• OpRegen Strengths & weaknesses relative to competitors

OpRegen Regulatory & Commercial Milestones

• OpRegen Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OpRegen Clinical Differentiation

• OpRegen Efficacy & safety advantages over existing drugs
• OpRegen Unique selling points

OpRegen Market Report Highlights

• In the coming years, the OpRegen market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OpRegen companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OpRegen's dominance.
• Other emerging products for Dry age-related macular degeneration and Dry macular degeneration are expected to give tough market competition to OpRegen and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OpRegen in potential indications.
• Analyse OpRegen cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OpRegen sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OpRegen in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of OpRegen? How strong is OpRegen's clinical and commercial performance?
• What is OpRegen's clinical trial status in each individual indications such as Dry age-related macular degeneration and Dry macular degeneration and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OpRegen Manufacturers?
• What are the key designations that have been granted to OpRegen for potential indications? How are they going to impact OpRegen's penetration in various geographies?
• What is the current and forecasted OpRegen market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OpRegen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OpRegen for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is OpRegen? What is the duration of therapy and what are the geographical variations in cost per patient?